The authors report on a fatal case of severe tetanus in a 74-year old woman. Despite comprehensive intensive care management they could not achieve a satisfying control of the autonomic dysfunction caused by tetanus. By now there is no established therapy for the treatment of the autonomic dysfunction. This report demonstrates the dismal prognosis of severe tetanus in the older people, which is often complicated by cardiovascular comorbidity and underlines the importance of tetanus prevention by sufficient vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128371 | PMC |
| http://dx.doi.org/10.1136/bcr.04.2011.4100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How to improve pertussis vaccination in pregnancy: a European expert review.
Expert Rev Vaccines
March 2025
Centre for the Evaluation of Vaccination, Vaccinopolis, University of Antwerp, Wilrijk, Belgium.
Introduction: Pertussis vaccination in pregnancy is a safe and highly effective strategy to protect young infants against severe pertussis, but cases continue to occur. In November 2023, the authors of this paper met to discuss difficulties faced by pertussis vaccination programs in pregnant women in Europe, and the need and potential for new vaccines.
Areas Covered: We summarize current pertussis epidemiology, the status of pertussis vaccination in pregnancy in Europe, followed by a summary of the meeting on benefits of pertussis-only vaccines and pertussis vaccines with improved immunogenicity, including a review of available vaccines.
A Phase 2b Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 6-Valent Group B Streptococcus Vaccine Administered Concomitantly With Tetanus, Diphtheria, and Acellular Pertussis Vaccine in Healthy Nonpregnant Female Individuals.
J Infect Dis
February 2025
Vaccine Research and Development, Pfizer, Pearl River, NY, USA.
Background: Maternal group B streptococcus (GBS) infection is associated with substantial risk of preterm birth and infant mortality. Preventative approaches to protect infants from GBS infection are needed.
Methods: In this phase 2b, randomized study, healthy nonpregnant 18-49-year-old females were randomized 1:1:1 to receive the investigational 6-valent GBS polysaccharide conjugate vaccine (GBS6) and concomitant Tdap (GBS6+Tdap), GBS6 and placebo (GBS6+placebo), or Tdap and placebo (Tdap+placebo).
Deadly Injuries Sustained From a Hyena Attack: The Importance of Timely Diagnosis and Treatment - A Case Report.
Open Access Emerg Med
February 2025
Department of ENT, Mogadishu Somali Turkey Training and Research Hospital, Mogadıshu, Somalia.
Animal bites represent a significant global public health concern, with hyena attacks being rare but highly destructive. This report details the case of a 22-year-old male who was attacked by a hyena while herding camels in rural Qardho, Somalia. The attack resulted in traumatic amputation of both testicles and the penis, finger loss, extensive muscle damage, and a jawbone fracture.
View Article and Find Full Text PDFDeep profiling of B cells responding to various pathogens uncovers compartments in IgG memory B cell and antibody-secreting lineages.
Sci Adv
February 2025
Amsterdam Institute for Immunology and Infectious diseases, Amsterdam, Netherlands.
Improving our understanding of B cell transition to memory B cells (MBCs) and antibody-secreting cells (ASCs) is crucial for clinical monitoring and vaccine strategies. To explore these dynamics, we compared prepandemic antigen responses (influenza hemagglutinin, respiratory syncytial virus fusion glycoprotein, and tetanus toxoid) with recently encountered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen responses in convalescent COVID-19 patients using spectral flow cytometry. Our analysis revealed the CD43+CD71+IgG+ activated B cell subset, highly enriched for SARS-CoV-2 specificities, as a juncture for ASC and MBC differentiation, with CD86+ phenotypically similar to ASCs and CD86- to IgG+ MBCs.
View Article and Find Full Text PDFRespiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates.
JAMA Netw Open
February 2025
Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco.
Importance: Two interventions to prevent severe respiratory syncytial virus (RSV) in infants were approved in 2023-a bivalent prenatal RSV prefusion F protein-based (RSVpreF) vaccine and an infant monoclonal antibody (nirsevimab). Understanding their uptake and clinical outcomes is essential for public health planning.
Objective: To describe uptake of the prenatal RSVpreF vaccine and infant nirsevimab.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!